Ortho-Cyclen-Birth-Control.com - Ortho Side Effects News

Ortho Side Effects News

Ortho Tri Cyclen review: A birth control pill with multiple advantages - Ortho Tri Cyclen Saturday, January 3, 2009 @ 6:16PMDo you associate birth control pills with side affects such as acne or hairiness? Forget about that. Ortho Tri Cyclen is a mild compound of hormones that prevents pregnancy and gets rid of acne.
Focus on the World Agricultural and Environmental Diagnostics Market Friday, December 19, 2008 @ 4:30AM NEW YORK----Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue.
Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks Of Fentanyl Overdose Tuesday, December 16, 2008 @ 5:10AMThe law firm of Hissey Kientz, LLP wishes to alert patients who use the Duragesic (fentanyl) pain patch of the serious and potentially fatal health risks they may face from the use of this powerful painkilling drug. The Duragesic pain patch was first approved by the Food and Drug Administration in August 1990 to treat certain patients with chronic pain.
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership ... Monday, December 15, 2008 @ 12:24PM Arena Pharmaceuticals, Inc. announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the glucose-dependent insulinotropic receptor for the treatment of type 2 diabetes.
Paliperidone palmitate shows positive results for treatment of schizophrenia Sunday, December 14, 2008 @ 9:18PMPaliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer Sunday, December 14, 2008 @ 11:19AM Results from a Phase 3 study show that patients with metastatic breast cancer who were treated previously with an anthracycline in the adjuvant setting experienced a significant improvement in time to disease progression and overall response rates after receiving a combination of DOXIL® and docetaxel as compared to docetaxel alone.
Hissey Kientz, LLP Warns Duragesic Patch Users About Potential Health Risks of Fentanyl Overdose Saturday, December 13, 2008 @ 2:13AM Hissey Kientz, LLP wishes to alert patients of the serious and potentially fatal health risks they may face from using the Duragesic (fentanyl) pain patch. Patients who are directly exposed to the gel inside the patch, or who received an excessive fentanyl dose because of other factors, may develop respiratory depression or other serious and potentially fatal side effects. (PRWeb Dec 13, 2008) ...
Phase 3 Data Demonstrate Efficacy And Tolerability Of Paliperidone Palmitate, An Investigational Long Acting Therapy ... Thursday, December 11, 2008 @ 5:13AMPaliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study presented today (1). Statistical significance was evidenced at all doses tested (25, 100, and 150 mg equivalent [eq.a]), when given every 4 weeks with a 150 mg eq. initiation dose.
Minimum Standards Of Care For Epilepsy Proposed By Experts Tuesday, December 9, 2008 @ 12:14PMLeading epilepsy specialists met at the American Epilepsy Society annual meeting in Seattle to unveil a recently published consensus report that proposes minimum standards of care for diagnosing, treating and monitoring epilepsy.
Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG Tuesday, December 9, 2008 @ 7:00AM dose, Weekly Contraceptive Patch to be Presented at ACOG Meeting in May 2009
Experts Propose Minimum Standards of Care for Epilepsy Monday, December 8, 2008 @ 12:28PMLeading epilepsy specialists met today at the American Epilepsy Society annual meeting in Seattle to unveil a recently published consensus report that proposes minimum standards of care for diagnosing, treating and monitoring epilepsy. Primary among these is the need for a detailed medical history, neurological examination, discussions with caregivers and diagnostic tests to make a diagnosis, as ...
Experts propose minimum standards of care for epilepsy Monday, December 8, 2008 @ 12:18PM( Golin/Harris International ) Leading epilepsy specialists met today at the American Epilepsy Society annual meeting in Seattle to unveil a recently published consensus report that proposes minimum standards of care for diagnosing, treating and monitoring epilepsy. Primary among these is the need for a detailed medical history, neurological examination, discussions with caregivers and ...
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity Monday, December 8, 2008 @ 7:00AM Arena Pharmaceuticals, Inc. announced today publication of the Phase 2b clinical trial results of lorcaserin, its novel drug candidate for the treatment of obesity, in the December 4, 2008 issue of Obesity, the official peer reviewed journal of The Obesity Society.
Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With ... Saturday, December 6, 2008 @ 11:00AM Researchers today report that after the implementation of Medicare coverage limitations for erythropoiesis-stimulating agents , a significantly greater proportion of anemic cancer patients who were on chemotherapy and who received ESAs needed blood transfusions and utilized more units of blood per patient than those patients who received ESAs prior to implementation of coverage limitations.
Hayes Says New Treatments for Pediatric Bipolar Disorder Not Ready for Prime Time Wednesday, December 3, 2008 @ 8:40AM LANSDALE, Pa.----Hayes, Inc., a leading medical technology research and consulting firm, has completed an exhaustive evaluation of clinical evidence behind popular treatments for pediatric Bipolar Disorder.
Tapentadol Immediate Release Tablets Approved For The Treatment Of Moderate To Severe Pain By FDA Friday, November 28, 2008 @ 5:05AMGrunenthal GmbH announces that the U.S. Food and Drug Administration (FDA) has approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain for adults 18 years and older.
FDA Approves New Drug To Alleviate Moderate To Severe Pain Wednesday, November 26, 2008 @ 7:21AMThe U.S. Food and Drug Administration has approved Tapentadol hydrochloride, an immediate-release oral tablet for the relief of moderate to severe acute pain. Tapentadol is a centrally-acting synthetic analgesic that is available in doses of 50 mg, 75 mg, or 100 mg.
FDA Approves New Drug To Alleviate Moderate To Severe Pain Wednesday, November 26, 2008 @ 5:52AMThe U.S. Food and Drug Administration has approved Tapentadol hydrochloride, an immediate-release oral tablet for the relief of moderate to severe acute pain.
NASA ISS On-Orbit Status 23 November 2008 Tuesday, November 25, 2008 @ 2:33PMAll ISS systems continue to function nominally, except those noted previously or below. Sunday Flight Day 10 (FD10) of STS-126/ULF-2. ISS crew work cycle today: Wake 8:55am EST; sleep 12:25am; Shuttle crew: 12:55am (both until 8:55am tomorrow).
An Easy Way to Reduce the Price at the Pump Wednesday, November 19, 2008 @ 4:46PM(ARA) - Want to save up to 12 cents a gallon off your gasoline bill? Invest in a tire gauge and make sure your tires are properly inflated.
Metabolex Announces Positive Results From Phase 2 Clinical Trial Of MBX-8025 Wednesday, November 19, 2008 @ 5:15AMMetabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025. A summary of the results was presented at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) on November 1, 2008.
Navasota Examiner Tuesday, November 18, 2008 @ 3:17PM(ARA) - First-time buyers account for a third of all-terrain vehicle sales each year. As with any major purchase, a little education can go a long way towards helping you get the best possible deal for your money.
Metabolex Announces Positive Results from Phase 2 Clinical Trial of MBX-8025 Tuesday, November 18, 2008 @ 7:30AM Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 2 clinical trial of MBX-8025.
Data From Investigational Use Of PROCRIT® (Epoetin Alfa) Presented At American Society Of Nephrology Annual Meeting Saturday, November 8, 2008 @ 5:17AMData from an investigational, open-label, randomized study assessing extended dosing regimens of PROCRIT® (Epoetin alfa) in treating anemia in subjects with Stages 3 - 4 chronic kidney disease (CKD) were presented at the American Society of Nephrology 41st Annual Meeting.
Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting Friday, November 7, 2008 @ 12:05PM Data from an investigational, open-label, randomized study assessing extended dosing regimens of PROCRIT® in treating anemia in subjects with Stages 3 - 4 chronic kidney disease were presented today at the American Society of Nephrology 41st Annual Meeting.
Alkermes Announces Second Quarter Fiscal 2009 Results Thursday, November 6, 2008 @ 3:25PMAlkermes, Inc. (NASDAQ: ALKS) today announced financial results for its second quarter of fiscal 2009. Financial highlights for the quarter ended September 30, 2008 include:
Alkermes Announces Second Quarter Fiscal 2009 Results Thursday, November 6, 2008 @ 3:00PM CAMBRIDGE, Mass.----Alkermes, Inc. today announced financial results for its second quarter of fiscal 2009. Financial highlights for the quarter ended September 30, 2008 include: A profitable quarter on a GAAP basis, with net income of $1.7 million.
Treatment With Paliperidone ER Significantly Improves Symptoms Of Schizoaffective Disorder, Study Monday, November 3, 2008 @ 5:33AMPatients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a new study presented today at the U.S. Psychiatric & Mental Health Congress in San Diego, Calif.
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder Saturday, November 1, 2008 @ 4:15PM Patients with schizoaffective disorder receiving paliperidone extended release tablets for six weeks showed a significant improvement in their symptoms, according to a new study presented today at the U.S.
Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results Thursday, October 30, 2008 @ 3:03PM Arena Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2008.
Tips for Buying Your First All-terrain Vehicle Friday, October 24, 2008 @ 3:41PM(ARA) - First-time buyers account for a third of all-terrain vehicle sales each year. As with any major purchase, a little education can go a long way towards helping you get the best possible deal for your money.
New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies ... Thursday, October 23, 2008 @ 12:19PM Masimo, the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that 13 new independent and objective clinical studies presented at the American Society of Anesthesiology Annual Meeting in Orlando, Fla., October 19-21, 2008, found Masimo SET® and Masimo Rainbow SET® technologies to be crucial in providing clinicians with an early indication ...
Volvo: Automaker is still on a roll Tuesday, October 21, 2008 @ 11:30PM Someone a long time ago told me that Volvo means "rolling."
FDA Approves New Injection Site For RISPERDAL(R) CONSTA(R) For Schizophrenia Treatment Friday, October 10, 2008 @ 11:07AMAlkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL® CONSTA® [(risperidone) Long-Acting Injection]. The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia.
FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment Thursday, October 9, 2008 @ 3:35PMAlkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection). The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia. RISPERDAL CONSTA was previously ...
Business And Careers Thursday, October 9, 2008 @ 3:23PM(ARA) - This presidential election seems like it has lasted an eternity, and to many people in the United States, it is a critical one. This has both good and bad consequences.
FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment Thursday, October 9, 2008 @ 3:05PM Patients with schizophrenia now have a new administration option for RISPERDAL® CONSTA® . The U.S. Food and Drug Administration has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia.
FDA Approves New Injection Site for RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment Thursday, October 9, 2008 @ 3:05PM CAMBRIDGE, Mass.----Alkermes, Inc. today announced that patients with schizophrenia now have a new administration option for RISPERDAL® CONSTA® [ Long-Acting Injection ]. The U.S. Food and Drug Administration has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia.
Unbranded Ads Also Unpopular Sunday, September 28, 2008 @ 7:09PMThe money pharmaceutical companies are spending on ads is in decline for the first time ever. This has caused a dramatic collapse in an area that companies have always proudly backed: unbranded health education campaigns.
More options for birth control Friday, September 26, 2008 @ 2:13AMWomen who use nonpermanent birth control to prevent unwanted pregnancies now have a host of options from which to choose, and most don’t require the daily vigilance that the traditional pill does, say women’s health experts here.
Ursula Hamann creates art with X-ACTO knife Tuesday, September 23, 2008 @ 3:26AMWith an impish gleam in her eyes, Ursula Hamann delights the listener with the fantasy tales of her paper cutting artwork. Genetically destined to be an artist, she began her art career working in oils and watercolor.
EU approves VELCADE for all stages of multiple myeloma Wednesday, September 10, 2008 @ 2:33AMHIGH WYCOMBE, England – Sept. 9, 2008 – The European Commission has approved VELCADE® in combination with melphalan and prednisone for the first-line treatment of patients with multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
VELCADE(x) for multiple myeloma receives front-line approval in Canada Tuesday, September 9, 2008 @ 7:00AM VELCADE for Injection has received Health Canada approval for front-line treatment of multiple myeloma, a fatal blood cancer. As part of combination therapy, VELCADE is indicated for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell transplantation.
New Survey Reveals Communication Gap Between Healthcare Professionals and Pain Patients Monday, September 8, 2008 @ 7:00AM A nationwide survey found a sizable gap exists between patients and healthcare professionals when it comes to understanding and discussing pain. To address this discrepancy, a new coalition of leading pain management organizations has formed to improve how patients and healthcare professionals communicate with each other.
Ortho Biotech Files sNDA for DOXIL(R) for the Treatment of Advanced Breast Cancer Monday, September 8, 2008 @ 6:00AM Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application to the U.S. Food and Drug Administration for the combination of DOXIL® and Taxotere® * for the treatment of women with advanced breast cancer who have received prior anthracycline treatment.
VELCADE(R) (Black Triangle Drug) (bortezomib) Approved For Previously Untreated Multiple Myeloma Monday, September 8, 2008 @ 5:20AM Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of
Learn about the World CNS Therapeutics Market Thursday, September 4, 2008 @ 5:51PM Reportlinker.com announces that a new market research report related to the Neurology industry is available in its catalogue.
Things to Know Before You Tow Wednesday, September 3, 2008 @ 9:38AM(ARA) - Even with gas at $4 a gallon, many people will soon be hitching up their boats, trailers and RVs and hitting the road for summer vacations. Catching up on the latest safety features will help these weekend warriors get out on the open road quickly and safely.
Business And Careers Tuesday, September 2, 2008 @ 9:18AM(ARA) - Each year, anti-discrimination laws open the doors to higher learning for millions of disabled students.
Improving Understanding of Epilepsy Thursday, August 28, 2008 @ 5:18AM(ARA) - Kelly Richards of Westmont, Ill., is committed to paving the way for her daughter Carly to have as normal a childhood as possible and to reduce the rejection and teasing she faces as a 14-year-old with epilepsy.